29 August The Polish Financial Supervision Authority approved the Prospectus of the Company, which means that its first listing on the Warsaw Stock Exchange may take place this autumn.
Celon Pharma S.A. will be the first biopharmaceutical company which at the same time specialises in developing, manufacturing and marketing of specialised generic drugs, as well as conducting research on innovative therapies to be listed on the Warsaw Stock Exchange.
IPO is an element of our long-term plan, the foundations of which we have been building from the beginning of the Company' operation. Our business model is effective and has been yielding good results for many years – says Maciej Wieczorek, President of Celon Pharma S.A. – Our ultimate goal is the development and manufacture of specialised prescription drugs which are the answer to unmet clinical needs.
Please note that:
1) This material is intended for promotional purposes only,
2) The Prospectus will be published in connection with the public offering of B Series Shares and the intention to apply for admission to trading of A2 Series shares, B Series shares and B series allotment certificates of Celon Pharma with its registered seat in Kiełpin in the regulated market (Mercurius Dom Maklerski sp. z o.o. is the investment company).
3) The Prospectus will be available on the website of the Offerer, i.e. Mercurius Dom Maklerski Sp. z o.o. (www.mercuriusdm.pl) and the website of Celon Pharma S.A. (www.celonpharma.com).
This material does not constitute any offer or proposal to acquire financial instruments, nor should it be regarded as a source of knowledge sufficient to make investment decisions.
The only legally binding document containing information about Celon Pharma S.A. and its shares, including the first public offering, is the Prospectus which will be made available in the above-mentioned locations. Investors interested in participating in the first public offering of Celon Pharma S.A. shares should carefully read the entire Prospectus and only after having analysed the entire document should they make any investment decisions regarding Celon Pharma S.A. shares. The first public offering of Celon Pharma S.A. shares will be carried out on the basis of the above-mentioned prospectus solely in the territory of the Republic of Poland. Outside the territory of the Republic of Poland this prospectus cannot be treated as a basis for offering or proposing the purchase of Celon Pharma S.A. shares.
In view of the above, the responsibility for the use of the information contained in this material rests entirely on the person using this material.